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We examined if multilocus sequence typing (MLST), a method for genotyping and species identification of
Burkholderia cepacia complex bacteria, could be applied directly to cystic fibrosis sputum. The redesigned
nested-PCR MLST format was successfully used to accurately identify strains in 23 sputum samples, of which
8 were culture negative.
Burkholderia cepacia complex (BCC) organisms have the
capacity to spread within populations of patients with cystic
fibrosis (CF) and to cause serious epidemic outbreaks (6, 16).
Strict infection control measures are therefore in place in many
CF centers to prevent person-to-person transmission of the
organisms. Correct identification of BCC organisms in clinical
specimens is an essential prerequisite for implementing a suc-
cessful infection control system. The 17 bacterial species that
form the BCC taxonomic cluster today (9, 12, 13) can only be
accurately distinguished from each other by applying molecu-
lar genetic methods. Although several protocols have been
developed to discriminate individual species (4, 8, 10), multilo-
cus sequence typing (MLST) has proven to be the only method
which has kept pace with the increasing complexity of BCC
species. By sequence analysis of seven housekeeping genes,
MLST enables unequivocal identification of all established
BCC species and also has the advantage of being able to define
novel BCC groups (1, 3, 7). In addition, it can serve as a highly
standardized genotyping method that provides robust informa-
tion on strain type, by defining a sequence type (ST).
There is great potential in DNA-based identification meth-
ods, as they provide the possibility to detect minute quantities
of BCC bacteria directly in clinical specimens. We previously
described a diagnostic nested recA PCR with excellent sensi-
tivity (5) that enabled the detection of BCC bacteria in sputum,
weeks to months before patients became culture positive. Such
direct PCR testing narrowed the diagnostic window between
the time of the initial BCC infection and laboratory diagnosis
and had a great impact on implementing infection control in
advance of what was routine with conventional microbiology.
Using direct PCR analysis, several instances of samples that
were BCC positive by PCR, but not by culture, were identified.
Follow-up of such cases was rather limited, as the recA PCR we
used (5) did not allow strain identification, and with no culture
to examine, conventional typing methods were ineffective. Yet
obtaining the strain type information for such patients is vital
in understanding the epidemiology behind their infection with
BCC bacteria. All gel pattern-based genotyping systems such
as pulsed-field gel electrophoresis require pure bacterial cul-
tures that were not available in the reproducibly PCR-positive,
but culture-negative patients. Although MLST is also a typing
method primarily designed to work from pure bacterial cul-
tures, in principle since it is based on DNA and PCR amplifi-
cation, its applicability to samples where bacteria are present in
a small, noncultivable amount was not ruled out.
We hypothesized that typing of the low quantities of BCC
strains in such PCR-positive cultures was feasible without the
need for obtaining pure cultures, if MLST was directly applied
to total DNA extracted from sputum. In order to increase
MLST sensitivity and to make it comparable to double-round
PCR-based detection of BCC from sputa (5), the original
MLST protocol for BCC (1) was modified to a redesigned
nested-PCR format. The primers used for sequence analysis in
the original MLST method already formed a primer pair that
was internal to the allele-specific amplification primers. There-
fore, they were employed, in addition to sequencing, for a
second round of the nested PCR.
To investigate the applicability of MLST for direct sputum
genotyping of BCC bacteria, 23 sputum samples from 17 CF
patients were examined (Table 1). The sputum samples were
representatives of the following diagnostic eventualities: (i) the
extent of BCC positivity, as determined by nested PCR, with 9
samples positive at round 1 and 14 positive only after 2 rounds
of this nested PCR; (ii) the differential ability to cultivate BCC
organisms, with 8 culture-negative and 15 culture-positive sam-
ples; (iii) situations involving multiple BCC species, as identi-
fied by the recA species-specific PCRs, with 10 Burkholderia
cenocepacia IIIA, 2 B. cenocepacia IIIB, 4 Burkholderia mul-
tivorans, and 3 Burkholderia stabilis samples, as well as 4 sam-
ples of indeterminate BCC species; and (iv) presence/absence
of coinfection with Pseudomonas aeruginosa (10 samples cul-
ture positive and 13 culture negative for P. aeruginosa). In
addition, for four of the patients studied, sputa were sampled
at multiple clinic visits: for 3 patients (patients 10, 14, and 17;
Table 1), two samples were obtained 5, 2, and 9 months apart,
respectively, and for patient 9, four consecutive samples were
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received at time intervals of 1, 6, and 7.5 months from the first
sampling point.
The PCR conditions for MLST round 1 amplification were
as follows. A PCR for each MLST allele was carried out in a
20-l volume with 2.0 mM MgCl2, 0.2 mM deoxynucleoside
triphosphates (dNTPs), 10 pmol “amplification primers” (1),
1 Q solution, and 0.75 U Taq polymerase (all PCR reagents
were obtained from Qiagen, Hilden, Germany) and 1 l bac-
terial DNA extracted from clinical samples with an Amplicor
respiratory specimen preparation kit (Roche, Indianapolis,
IN). The PCR program was run on a TGradient thermocycler
(Biometra, Goettingen, Germany) with initial denaturation for
5 min at 96°C and a subsequent 30 cycles of 30 s at 96°C, 30 s
at 55°C, and 2 min at 72°C. An internal DNA fragment was
then amplified in a second PCR with reaction chemistry iden-
tical to round 1, except that the sequencing primers (1) and 1
l PCR product from round 1 were incorporated. The thermal
cycling profile for round 2 was as follows. Initial denaturation
was at 96°C for 2 min followed by a subsequent run of 35
cycles, each comprising 15 s at 96°C, 30 s of annealing (see
below), and 45 s at 72°C. The annealing temperature was set to
decrease from 60°C in the first cycle by 0.5°C per cycle over the
next 10 cycles to reach the final annealing temperature of 55°C,
which was then kept for the last 25 cycles of PCR. The detec-
tion limit of the nested PCR was determined by serial decimal
dilutions of DNA from a B. cenocepacia culture of known
viability that had been extracted in the same way as the sputum
samples.
Successful MLST data were obtained for every sample ex-
amined, including those samples which were culture negative
and those which were amplification negative after 1 round of
the recA diagnostic PCR (summarized in Table 1). If a single
MLST allele was not detected after completion of the first
MLST-PCR round, all seven genes of the sample were sub-
jected to the round 2 PCR. The threshold of this setup was
found for each of the seven MLST genes at 104 CFU/ml (10
CFU per reaction). Out of 161 sequencing PCRs performed
(23 samples  7 MLST genes), only one reaction failed re-
peatedly to give a readable sequence (the phaC allele for
sample 5445); however a complete ST profile for this strain was
TABLE 1. Characteristics of sputum samples examined in this study
Patient Sample ID no.
Identification of BCC by nested PCR and culture MLST analysis of BCC
PCR round at
which detected Species identified Culture ST Species identified
1 5884 1 B. cenocepacia IIIA  32 B. cenocepacia IIIA
2 6140 1 B. cenocepacia IIIA  32 B. cenocepacia IIIA
3 5475 1 B. cenocepacia IIIA  32 B. cenocepacia IIIA
4 5938 2 B. cenocepacia IIIA  32 B. cenocepacia IIIA
5 5883 2 B. cenocepacia IIIA  211 B. cenocepacia IIIA
6 5780 2 B. cenocepacia IIIA  234 B. cenocepacia IIIA
7 6144 1 B. cenocepacia IIIA  234 B. cenocepacia IIIA
8 5911 1 B. cenocepacia IIIA  234 B. cenocepacia IIIA
9 4871 2 Indeterminate  102, 482 B. contaminans
4941 1 B. cenocepacia IIIA  482 B. contaminans
5315 1 B. cenocepacia IIIA  102, 482 B. contaminans
5445 2 Indeterminate  482 B. contaminans
10 5662 2 Indeterminate  102 B. contaminans
6070 2 Indeterminate  102 B. contaminans
11 5983 1 B. cenocepacia IIIB  184 B. cenocepacia IIIB
12 6072 2 B. cenocepacia IIIB  184 B. cenocepacia IIIB
13 5699 1 B. multivorans  180 B. multivorans
14 5781 2 B. multivorans  564 B. multivorans
5984 2 B. multivorans  564 B. multivorans
15 5747 2 B. multivorans  562 B. multivorans
16 4894 2 B. stabilis  51 B. stabilis
17 4934 2 B. stabilis  563 B. stabilis
5702 2 B. stabilis  563 B. stabilis
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obtained from another sample from the same patient (Table
1). Thus, we did not have to exploit alternative primers which
were recently redesigned in order to achieve more reliable
amplification results for all BCC groups and other Burkhold-
eria species (11).
At the level of species identification, the direct MLST anal-
ysis outperformed the original recA-based diagnostic PCR (5).
MLST provided correct species identification in 4 samples that
were left undetermined by recA species-specific PCR (Table 1;
patients 9 and 10). All of these samples were assigned to the
recently described species Burkholderia contaminans, a rele-
vant pathogen in CF (7, 12), for which no species-specific recA
PCR has been described. In addition, MLST corrected previ-
ous species misidentification of two B. contaminans isolates
from patient 9 (Table 1) which had been misclassified as B.
cenocepacia IIIA with recA species-specific PCRs. This finding
is in agreement with recent studies (3, 4) that highlight poten-
tial problems in BCC species identification performed solely
with first-generation molecular identification approaches, such
as recA restriction fragment length polymorphism (RFLP) or
recA species-specific PCRs; sequence analysis of the recA gene
as part of the MLST is far more accurate than these indirect
ways of examining DNA polymorphisms.
Analysis of two sputum samples from patient 9 (ID 4871 and
5315; Table 1) revealed the coexistence of two distinct strains
of B. contaminans (ST102 and ST482). These two strains differ
from each other by all seven MLST alleles, out of which the
gyrB gene carries the most pronounced sequence polymor-
phisms (18-nucleotide difference). Nucleotide sequence differ-
ences for each allele variant were clearly apparent in the se-
quence traces obtained (Fig. 1). Clearly discernible composite
nucleotide peaks were observed at each nucleotide polymor-
phism site that could be readily separated into the two discrete
allele sequences. Consequently, the presence of both strains
was tracked down and confirmed by more thorough analysis of
the culture that was isolated from sputum ID 4941 and that
alone showed an MLST result corresponding only to one of the
two strains. By screening the sequences of the gyrB allele of 50
individual colonies which were isolated from the parental cul-
ture ID 4941, we detected gyrB 76 (i.e., ST102) in five colonies.
While this may have indicated that the ST482 strain was the
more predominant strain from the pair, neither strain persisted
and caused chronic infection, as 5 subsequent samples col-
lected over the period of 1 year were BCC free (data not
shown). Although coinfection and strain replacement with dif-
ferent BCC species have been previously demonstrated in CF
(2, 14, 15), such studies required the cultivation and purifica-
tion of each strain present, which may not always be possible if
the colonial morphology of each isolate is not discriminatory.
Direct MLST as described here enabled the detection of mixed
BCC populations in an analysis without the need for strain
separation. Nevertheless, this ST identification approach
brings a potential limitation in that we selected a combination
of 7 out of 14 obtained alleles (7 alleles  2 strains) based on
known profiles submitted to the public MLST database (http://
pubmlst.org/bcc/); without an option to validate a not-yet-de-
scribed combination of alleles, this method would not allow
identification of a completely new ST. In addition, definition of
the correct 7-allele combination would have been impossible if
we had detected multiple shared alleles that occur in multiple
STs, including the two in question. The ST assembly derived
for the two B. contaminans strains (Table 1) was simplified by
the fact that every allele was either unique for one strain or did
not occur in combination with other alleles for the other strain.
Potential cross-reactivity with DNA of another origin was
one of our major concerns about the applicability of MLST
directly to sputum. However, we obtained unambiguous se-
quencing results from both PCR rounds, which indicated that
neither human DNA nor non-BCC bacterial DNAs (such as P.
aeruginosa) that were present in inflammatory CF sputum did
interfere with the MLST protocol.
In conclusion, we have demonstrated that BCC strain iden-
tification is feasible directly from sputum samples without a
need to work with pure cultures. We found this method useful
FIG. 1. Identification of two B. contaminans strains within the sputum of patient 9. The sequence trace file of the gyrB allele resulting from
MLST analysis of clinical sample ID 5315 is shown. Two distinct strains (ST102 and ST482) were present in the sample, and nucleotide
polymorphisms representing each allele of the two STs (i.e., gyrB 76 and gyrB 245) are highlighted; positions of nucleotide differences in allele
sequence are indicated above the bars.
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particularly in situations where culture results remain negative
due to a low bacterial load during infection. In such cases, only
direct MLST on sputum can provide information on strain type
and facilitate the complete analysis of a local epidemiological
situation, a vital prerequisite for effective BCC surveillance
and infection control in every CF center.
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